CLASS II ONGOING Device recall · Reported 28 Dec 2022 · FDA Enforcement Report

InPen Diabetes Management App, part of the InPen System recalled

Companion Medical is recalling InPen Diabetes Management App, part of the InPen System, distributed nationwide in the US. The recall was initiated on 8 Nov 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesInPen Software App for Android, versions 5.6.1.1 and 5.6.2 with InPen System REF/UDI-DI: MMT-105ELBLNA/10862088000313, MMT-105ELGYNA/10862088000320, MMT-105ELPKNA/10862088000337, MMT-105NNBLNA/10862088000344, MMT-105NNGYNA/10862088000351, MMT-105NNPKNA/10862088000368.
Quantity recalled140

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0741-2023
FDA event ID
91158
Recalling firm
Companion Medical, San Diego, CA
Classification
Class II
Status
Ongoing
Recall initiated
8 Nov 2022
FDA classified
20 Dec 2022
Reported
28 Dec 2022
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Other Reasons
Device type
Medical Software

Timeline

8 Nov 2022Recall initiated by company
20 Dec 2022Classified by FDA+42 days
28 Dec 2022Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Diabetes management app may crash immediately upon opening, while using the app and/or while app is running in the background, which may lead to inability to use the app. An error message may be displayed indicating the app has stopped or isn't responding. After the crash, a present dose reminder is not displayed, which may lead to delayed insulin therapy and potentially resulting in hyperglycemia.

Product as listed by the FDA

InPen Diabetes Management App, part of the InPen System, REF: MMT-105ELBLNA, MMT-105ELGYNA, MMT-105ELPKNA, MMT-105ELPKNA, MMT-105NNBLNA, MMT-105NNGYNA, MMT-105NNPKNA.

Where it was distributed

US Nationwide distribution including in the states of CA, NY, MT, OH, IN, MN, PA, CT, TX, WA, TN, SD, MI, FL, OR, NC, KY, WI, MO, WV, NV, SC, AZ, AR, MA, LA, VT, GA.

Nationwide ArkansasArizonaCaliforniaConnecticutFloridaGeorgiaIndianaKentuckyLouisianaMassachusettsMichiganMinnesotaMissouriMontanaNorth CarolinaNevadaNew YorkOhioOregonPennsylvania

Questions about this recall

Why was it recalled?

Diabetes management app may crash immediately upon opening, while using the app and/or while app is running in the background, which may lead to inability to use the app. An error message may be displayed indicating the app has stopped or isn't responding. After the crash, a present dose reminder is not displayed, which may lead to delayed insulin therapy and potentially resulting in hyperglycemia.

Which lots are affected?

InPen Software App for Android, versions 5.6.1.1 and 5.6.2 with InPen System REF/UDI-DI: MMT-105ELBLNA/10862088000313, MMT-105ELGYNA/10862088000320, MMT-105ELPKNA/10862088000337, MMT-105NNBLNA/10862088000344, MMT-105NNGYNA/10862088000351, MMT-105NNPKNA/10862088000368.

Where was it sold?

US Nationwide distribution including in the states of CA, NY, MT, OH, IN, MN, PA, CT, TX, WA, TN, SD, MI, FL, OR, NC, KY, WI, MO, WV, NV, SC, AZ, AR, MA, LA, VT, GA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other Medical Software recalls

All 903